日本語 
SOLA Biosciences Japan GK, the branch of the Boston-based company SOLA Biosciences Inc. has received about ¥6 billion in support from the Japan Agency for Medical Research and Development known as AMED. This funding is meant to help advance the company’s gene therapy program for lateral sclerosis or ALS.
The money will support the development of a treatment called SOL-257 over the five years. It is part of AMED’s Strengthening Program for Pharmaceutical Startup Ecosystem. AMED chose SOLA Biosciences Japan as the development partner for a gene therapy that targets misfolded TDP-43, a protein that plays a key role in the progression of ALS.
This grant puts SOLA Japan at the heart of the company’s work in Japan. It will help connect the research team in the United States with institutions in Japan and around the world. It will also link with development groups, manufacturing partners and investors.
SOL-257 Targets Misfolded TDP-43
SOL-257 is being designed to tackle TDP-43 proteins that build up in motor neurons in people with ALS. According to SOLA, mislocalization, misfolding and clumping of TDP-43 are seen in 97% of ALS cases. That makes TDP-43 a crucial focus for finding treatments.
Of just managing symptoms SOLA is working on SOL-257 to fix the root cause. The faulty protein. The goal is to restore the shape and function of misfolded TDP-43. If successful this could slow down the damage to motor neurons. Stop the disease from getting worse.
This treatment is still, in development. It has not been approved yet and more studies are needed to see if it works safely and effectively in people.
JUMP70 Platform Uses Protein Quality Control
SOL-257 was developed using SOLA’s proprietary JUMP70 platform, which is designed to selectively recognize disease-associated misfolded proteins while leaving normally functioning versions of those proteins intact.
The platform combines a disease-specific targeting component with a mechanism designed to activate the cell’s protein quality-control system. It works by recruiting HSP70, a molecular chaperone involved in protein folding and quality control, toward the targeted abnormal protein.
For SOL-257, the technology is directed toward misfolded TDP-43. SOLA says the program is intended to promote restoration of normal TDP-43 structure and function rather than simply removing the protein.
The company’s broader JUMP70 pipeline also includes programs targeting misfolded proteins associated with Huntington’s disease and Parkinson’s disease.
Japan Becomes a Key Development Hub
The AMED program gives SOLA an opportunity to establish a Japan-based development structure for a biotechnology program originating from a U.S. company.
SOLA Biosciences Japan plans to work with its U.S. team alongside domestic and international research institutions, clinical organizations and manufacturing partners. Curie.Bio is participating as the lead investor, while The University of Tokyo Edge Capital Partners (UTEC) is participating as a follow-on investor.
For Japan’s biotechnology sector, the arrangement illustrates how government-backed funding can connect overseas biotech companies with domestic research, clinical and manufacturing capabilities.
AMED’s official announcement lists SOLA Japan’s project as the development and commercialization of a gene therapy designed to restore the structure and function of misfolded TDP-43. The agency selected the project from 10 applications following its review process.
Toward Human Proof of Concept
Also Read: ITM and Lumara Bio Share New ITM-11 Cancer Therapy Information
Under the five-year program, SOLA intends to advance SOL-257 toward human proof of concept in both Japan and the United States and establish a foundation for subsequent global clinical development.
The funding does not by itself establish the clinical effectiveness or commercial viability of SOL-257. Additional development, clinical testing and regulatory evaluation will be required before its potential as an ALS therapy can be determined.
For Japanese pharmaceutical companies, biotech startups, contract research organizations and manufacturing partners, the program also highlights the growing role of cross-border development models in advanced therapies. As SOLA progresses SOL-257, collaboration between Japan’s research and manufacturing ecosystem and international biotechnology developers could become an important part of the program’s next stages.
English